Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Inventory (2021 - 2025)

Historic Inventory for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Q3 2025 value amounting to $24.0 million.

  • Mirum Pharmaceuticals' Inventory rose 1123.92% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.0 million, marking a year-over-year increase of 1123.92%. This contributed to the annual value of $22.4 million for FY2024, which is 40.79% up from last year.
  • According to the latest figures from Q3 2025, Mirum Pharmaceuticals' Inventory is $24.0 million, which was up 1123.92% from $22.9 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Inventory registered a high of $24.0 million during Q3 2025, and its lowest value of $1.5 million during Q4 2021.
  • Moreover, its 5-year median value for Inventory was $21.0 million (2024), whereas its average is $14.7 million.
  • Per our database at Business Quant, Mirum Pharmaceuticals' Inventory soared by 31854.43% in 2023 and then plummeted by 294.83% in 2024.
  • Over the past 5 years, Mirum Pharmaceuticals' Inventory (Quarter) stood at $1.5 million in 2021, then surged by 267.81% to $5.6 million in 2022, then soared by 300.93% to $22.3 million in 2023, then grew by 0.41% to $22.4 million in 2024, then rose by 7.22% to $24.0 million in 2025.
  • Its Inventory was $24.0 million in Q3 2025, compared to $22.9 million in Q2 2025 and $22.4 million in Q1 2025.